Bio-Techne Corp (TECH) and Its Competitors Head to Head Survey
Bio-Techne Corp (NASDAQ: TECH) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Bio-Techne Corp to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.
Institutional and Insider Ownership
98.4% of Bio-Techne Corp shares are held by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 3.4% of Bio-Techne Corp shares are held by company insiders. Comparatively, 14.3% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Bio-Techne Corp and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Bio-Techne Corp Competitors||-3,680.23%||-415.63%||-47.84%|
This is a breakdown of recent recommendations for Bio-Techne Corp and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Bio-Techne Corp Competitors||785||2925||6385||144||2.58|
Bio-Techne Corp currently has a consensus target price of $126.33, indicating a potential upside of 3.91%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.54%. Given Bio-Techne Corp’s competitors higher probable upside, analysts plainly believe Bio-Techne Corp has less favorable growth aspects than its competitors.
Risk and Volatility
Bio-Techne Corp has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Bio-Techne Corp’s competitors have a beta of 1.67, indicating that their average share price is 67% more volatile than the S&P 500.
Earnings and Valuation
This table compares Bio-Techne Corp and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Bio-Techne Corp||$563.00 million||$186.35 million||62.67|
|Bio-Techne Corp Competitors||$207.14 million||-$2.51 million||0.23|
Bio-Techne Corp has higher revenue and earnings than its competitors. Bio-Techne Corp is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Bio-Techne Corp pays an annual dividend of $1.28 per share and has a dividend yield of 1.1%. Bio-Techne Corp pays out 66.0% of its earnings in the form of a dividend. As a group, “Biotechnology & Medical Research” companies pay a dividend yield of 1.1% and pay out 66.0% of their earnings in the form of a dividend.
Bio-Techne Corp beats its competitors on 8 of the 13 factors compared.
Bio-Techne Corp Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.